The Advancing Management of Transthyretin Amyloidosis: A Practical Guide
Published: 26 August 2023
11m 43sPart 1 ATTR – A Multi-system Disease Posing Unique Challenges Julian Gillmore, Laura Obici, Martha Grogan, Arnt Kristen
16m 57sPart 2 Assessing Cardiac Manifestations of ATTR Martha Grogan, Julian Gillmore, Laura Obici, Arnt Kristen
15m 23sPart 3 Long-term Management Laura Obici, Julian Gillmore, Laura Obici, Arnt Kristen
Radcliffe Medical Education bring together a globally-renowned faculty, including Prof Julian Gillmore (University College London, London, UK) as he chairs a panel of distinguished experts, Dr Martha Grogan (Mayo Clinic College of Medicine, US), Dr Laura Obici (I.R.C.C.S. San Matteo Polyclinic, IT) and Prof Arnt Kristen (University of Heidelberg, Heidelberg, DE) in this interactive symposium covering the unique challenges of ATTR in diagnosis, assessment, long-term management and future treatment options.
During this session, the panel discussed key aspects related to ATTR-cm including the need for standardised and coordinated care, identifying disease progression and assessing quality of life after initiating treatment.
The programme also features short interactive video presentations and polls to provide you with practical knowledge and tools to implement ATTR-cm effectively in your clinical practice.
This Satellite Symposium was supported by an unrestricted educational grant from AstraZeneca who has no involvement in the content.
Presented, and recorded, at ESC 2023 in Amsterdam, NL
Key Learning Objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
- Heart Failure Specialist
- Cardiac Amyloidosis Specialist
More from this programme
ATTR – A Multi-system Disease Posing Unique Challenges
Commencing the inaugural session, Professor Julian Gillmore assumes the role of keynote presenter, elucidating the intricate diagnostic challenges at the forefront. Drawing upon his wealth of experience, Professor Gillmore adeptly delineates the nuanced junctures warranting early intervention, while advocating for the implementation of standardised and meticulously coordinated care pathways.
Assessing Cardiac Manifestations of ATTR
During Session 2, Dr Martha Grogan will discuss the cardiac implications of Transthyretin Amyloidosis (ATTR) and the diagnosis and monitoring of symptomatic cases with ATTR-cm. The presentation will include a patient journey depicted through an interactive video, supplemented by an audience poll to gather treatment-related responses.
In Session 3, Dr. Laura Obici focuses on tracking disease progression by evaluating multiple symptoms and their assessment frequency, involving various healthcare professionals. She concludes by discussing current guideline-based approaches for symptom management and disease modification. The session also includes a review of the patient case study's outcomes and audience poll results.
What’s in our Future Toolbox?
In the penultimate session, Professor Arnt Kristen will delve into the realm of innovative pharmacological management. His presentation will center on emerging disease-modifying therapies, with a particular emphasis on LICA, TTR stabilizers, silencers, and depleters.
Meeting Summary and Conclusions
Arnt Kristen practices in Heidelberg, Germany. His top areas of expertise are Primary Amyloidosis, Transthyretin Amyloidosis, Cardiac Amyloidosis, Heart Transplant, and Tissue Biopsy.
Julian Gillmore gained his medical degree at University of London. He trained in nephrology and undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.
Laura Obici practices in Pavia, Italy. Dr Obici and is regarded in 16 conditions. Her top areas of expertise are Transthyretin Amyloidosis, Primary Amyloidosis, Familial Transthyretin Amyloidosis, Cardiac Amyloidosis, and Tissue Biopsy.
Dr Martha Grogan, is a Former Chief of Internal Medicine and Medical Director, Assistant Warden, at the Federal Medical Center while fulfilling a National Health Service Corps commitment. Dr Grogan is the founder and director of the Cardiac Amyloid Clinic (2012), and has been the cardiovascular medical editor of the award-winning MayoClinic.com website for almost a decade. Lastly, conducts clinical research with a focus on cardiac amyloidosis and lectures widely.